Cagrilintide for weight loss: what the early trials actually show

What did @callmekt1 actually say?

The short version: they tried cagrilintide at 0.75mg and described it as doing "nothing" beyond roughly 10 hours of appetite suppression, calling the experience miserable. They floated the idea that fatigue, not the drug, was responsible for any reduced eating. That's an honest self-report, and honestly, it's more nuanced than most peptide content on this platform.

To be precise, the creator said ".75 milligrams of Kae did nothing for me. It made me miserable for 10 hours." They also suggested they "was just too tired" to eat, which raises a real methodological problem: if you can't separate drug effects from baseline exhaustion, you don't actually know what the compound did. That's not a criticism of the person, that's just the reality of self-experimenting without controls.

Does the science back this up?

The side effect profile is accurate. The short suppression window is harder to explain pharmacologically, and that's where things get interesting.

Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk. In the phase 2 SCALE data (Enebo et al., 2021, The Lancet), once-weekly cagrilintide produced dose-dependent weight loss from 0.3mg up to 4.5mg, with the 0.3mg dose still showing meaningful separation from placebo. The drug's half-life is approximately 7-8 days, which is why a 10-hour subjective suppression window at 0.75mg doesn't map neatly onto the pharmacokinetics. Subjective appetite suppression and drug plasma levels are not the same thing. The creator may have felt relief from side effects at 10 hours while the drug was still pharmacologically active.

Nausea, fatigue, and general misery in the early titration phase are well-documented. Enebo et al. reported gastrointestinal adverse events in over 50% of participants at higher doses, and even lower doses produced some GI burden. So "miserable for 10 hours" is consistent with the clinical record.

What did they get wrong (or right)?

They got the side effect experience right. The framing that cagrilintide "did nothing" is where the logic slips.

A compound with a multi-day half-life does not stop working after 10 hours. What the creator likely experienced was the peak side effect window fading, which is not the same as the drug becoming inactive. The COMBINE study data (Lau et al., 2023, Nature Medicine) on cagrilintide combined with semaglutide showed sustained metabolic effects across the full dosing interval, not a brief window. Conflating "I felt awful and then felt better" with "the drug stopped working" is a common and understandable error in self-reporting, but it's still an error.

Credit where it's due: the creator was appropriately tentative. They said "I think" and "maybe," which is the right epistemic posture when you're n=1 and confounded by fatigue. That kind of hedging is rare in peptide content and worth acknowledging.

What should you actually know?

Cagrilintide is not approved by the FDA as a standalone treatment. It is currently being studied in combination with semaglutide under the name CagriSema, and it is not available through legitimate licensed pharmacies as a finished, approved product in the United States. Anyone using it right now is using a research compound or compounded product, and the regulatory and quality-control implications of that are serious.

The OASIS and REDEFINE trial programs (ongoing as of 2024) are designed to evaluate CagriSema's safety and efficacy. We do not yet have long-term safety data on cagrilintide used in isolation at various doses in general populations. The titration schedule matters significantly. Starting at 0.75mg without clear clinical guidance on escalation is not something the existing trial data endorses for general use.

If you are fatigued, sleep-deprived, or metabolically stressed, your subjective response to appetite-suppressing compounds will be unreliable. That's not a drug problem, it's a measurement problem.